Bladder Cancer: Treatment Options and Managing Adverse Effects

The study population was able to avoid 952 cystoscopies and 71 CT scans, according to the investigators.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

"97% [of patients] remain progression free, and 84.5% avoided cystectomy, highlighting cretostimogene’s bladder-sparing potential,” said Mark D. Tyson II, MD, MPH.

“In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.